Tonka
Well-known member
http://www.prensa-latina.cu/index.php?option=com_content&task=view&id=328555&Itemid=1
Spanish to English translation
Burkina Faso: proven effectiveness of malaria vaccine
Ouagadougou, 24 sep (PL) A malaria vaccine developed by French and American scientists and tested in this West African country, showed encouraging results of efficacy and safety in research phase. So far, a hundred different molecules aspired to become the first effective vaccine against the disease, but the drug tested in Burkina Faso MSP3 is the second to achieve an appreciable level of protection, especially in children. The vaccine is based on MSP3 protein capable of inducing the body to produce antibodies suitable for killing the plasmodium, the parasite that causes malaria and malaria as it is also known. The double-blind randomized study involved 45 children divided into three groups, two of whom were immunized and they had a disease incidence of three or four times minor immune response almost identical. The first scientific results of the Pasteur Institute in Paris and the U.S. National Institutes of Health were published in The New England Journal of Medicine. More than one million 300 thousand people die each year from malaria , 90 percent of them children under five years. Nearly 400 million new cases appear every year, mostly in Africa, and more in the southern Sahara, where the alarm is due to the characteristics of the disease endemic to carry more or less asymptomatic. The first vaccine was developed by a group of scientists led by Colombian doctor Elkin Patarroyo at which effectiveness is recognized between 40 and 60 percent in adults and 77 children. car / smp
Spanish to English translation
Burkina Faso: proven effectiveness of malaria vaccine
Ouagadougou, 24 sep (PL) A malaria vaccine developed by French and American scientists and tested in this West African country, showed encouraging results of efficacy and safety in research phase. So far, a hundred different molecules aspired to become the first effective vaccine against the disease, but the drug tested in Burkina Faso MSP3 is the second to achieve an appreciable level of protection, especially in children. The vaccine is based on MSP3 protein capable of inducing the body to produce antibodies suitable for killing the plasmodium, the parasite that causes malaria and malaria as it is also known. The double-blind randomized study involved 45 children divided into three groups, two of whom were immunized and they had a disease incidence of three or four times minor immune response almost identical. The first scientific results of the Pasteur Institute in Paris and the U.S. National Institutes of Health were published in The New England Journal of Medicine. More than one million 300 thousand people die each year from malaria , 90 percent of them children under five years. Nearly 400 million new cases appear every year, mostly in Africa, and more in the southern Sahara, where the alarm is due to the characteristics of the disease endemic to carry more or less asymptomatic. The first vaccine was developed by a group of scientists led by Colombian doctor Elkin Patarroyo at which effectiveness is recognized between 40 and 60 percent in adults and 77 children. car / smp